Evotec
Melinda Barkhuizen, PhD, PMP, is a seasoned computational biologist currently working at Evotec, specializing in large-scale OMICs data to identify novel disease signatures in kidney and immunological diseases. Previous experience includes directing neuroinflammation research as a postdoctoral fellow at Philip Morris International, co-founding MagneFeCent Therapeutics to advance glioblastoma therapies, and conducting significant research on perinatal insults during a PhD at Maastricht University. Academic qualifications encompass dual PhDs in Neuroscience and Pharmaceutical Sciences, along with postdoctoral fellowship training in Neurology from UCSF. Melinda Barkhuizen has also contributed to scientific communication and community organization as a finance board member for the UCSF Postdoctoral Scholar Association and has experience as a pharmacist intern.
This person is not in any teams
This person is not in any offices
Evotec
5 followers
Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.